Keywords
Non-responsiveness
HIV
Renal Insufficiency, Chronic
Renal Dialysis
Biological therapy
PreHevbrio®
Fendrix®
Heplisav-B®
Hepatitis B vaccine AS04
How to Cite
Abstract
The recombinant DNA vaccine against Hepatitis B virus is the standard vaccine due to its high effectiveness. However, some patients have inadequate responses. This article seeks to describe HBV vaccination in special situations and the development of new vaccines. A search was conducted on PubMed and ScienceDirect using terms such as “Non- responsiveness,” “HIV,” “renal patients,” “dialysis patients,” “biological therapy,” and “Hepatitis B vaccine,” selecting 41 articles for review. In conditions such as HIV infection, chronic kidney disease, biological therapy, and non-responders due to genetic, immunological, and individual variables, there is a greater risk of not generating sufficient antibodies to achieve adequate immunization status. New vaccines (Fendrix®, Heplisav-B®, PreHevbrio®) have been developed which have shown better results, thus necessitating consideration of alternative vaccination approaches in special situations.
References
Tripathi N, Mousa OY. Hepatitis B. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [citado 13 de septiembre de 2023]. Disponible en: http://www.ncbi.nlm.nih. gov/books/NBK555945/
Dirección de Promoción y Prevención. Área Funcional Población y Desarrollo. Lineamiento para el tamizaje y la vacunación contra el virus de la hepatitis B a poblaciones vulnerables priorizadas, 2021. Colombia. Ministerio de Salud; 2021. Disponible en: https://www.minsalud. gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-vacunacion-hepatitis-B-poblaciones-vulnerables.pdf [citado 13 de septiembre de 2023]
Grupo de enfermedades transmisibles endoepidémicas y relacionadas con salud sexual. Protocolo de Vigilancia de Hepatitis B, C y coinfección/superinfección Hepatitis B-Delta. Colombia. Instituto Nacional de Salud; 2022. Disponible en: https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Hepatitis%20BCD.pdf [citado 13 de septiembre de 2023]
Goldman-Cecil. Tratado de medicina interna. 25 ed. España: Elsevier; 2016.
Sociedad Española de Geriatría y Gerontología. Recomendaciones de vacunación para adultos y mayores 2018-2019. Madrid. IMC; 2018. Disponible en: https://www.segg.es/media/descargas/SEGG-VACUNACION-2018-2019.pdf [citado 13 de septiembre de 2023]
AEP: Asociación Española de Pediatría. Hepatitis B. [citado 13 de septiembre de 2023]. Disponible en: https://www.aeped.es/sites/default/files/documentos/hepatitisB.pdf
Sánchez-Orozco LV, Panduro-Cerda A. Genómica y proteómica del virus de la Hepatitis B. Investigación en Salud [Internet]. 2005;VII(1):12-18. Disponible en: https://www.redalyc.org/articulo.oa?id=14270103
Desfilis-Serra MA. Virus de la Hepatitis B. SEIMC. 2003. Disponible en: https://www.seimc.org/contenidos/ccs/revisionestematicas/viromicromol/VHBrev.pdf
Moreno D, Alegre F, García-González N. Virología, epidemiología y mecanismos de transmisión del VHB. Anales Sis San Navarra. 2004;27(Suppl 2):7-16.
Martínez-Méndez DK, Barboza L, Hernández- Valles RC. Genotipos de Hepatitis B: Importancia clínica. Rev Soc Ven Microbiol. 2007;27(1):349- 363.
Moonnoom. Diagrama de la estructura de partícula del virus de la hepatitis B [Internet]. Dreamstime. 2018. Disponible en: https://es.dreamstime.com/diagrama-de-la-estructura-part%C3%ADcula-del-virus-hepatitis-b- image106407525
Jaramillo CM, Navas MC. Variantes de escape del virus de la hepatitis B. Rev chil infectol. 2015;32(2):190-197.
Mejía JA. Vacuna antihepatitis B: Vacunas y toxoides. En: Rodríguez Carranza R. eds. Vademécum Académico de medicamentos. Sexta edición. México: McGraw Hill; 2014. p. 642-643.
Paho.org [Internet]. Vacunas contra la hepatitis [citado el 22 de septiembre de 2023]. Disponible en: https://www.paho.org/es/tag/vacunas-contra-hepatitis
Colombia. Ministerio de Salud y Protección Social. Colombia avanza en la eliminación de la hepatitis B en niños. Boletín de Prensa No 121 de 2019 (Jul. 28, 2019). Disponible en: https://www.minsalud.gov.co/Paginas/Colombia-avanza-en-la-eliminacion-de-la-he patitis-B-en-ni%C3%B1os.aspx
Organización Mundial de la Salud [Internet]. Hepatitis B: 2023 Jul 18. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hepatitis-b
Colombia. Ministerio de Salud y Protección Social. Colombia avanza en la eliminación de las hepatitis B y C. Boletín de prensa No 175 de 2023 (Jul 28, 2023). Disponible en: https://www.minsalud.gov.co/Paginas/Colombia-avanza-en-la-eliminacion-de-las-hepatitis-B-y-C.aspx
Colombia. Instituto Nacional de Salud. Informe de evento HEPATITIS B, C y B-DELTA.. Código 340, 2021. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/ HEPATITIS%20BCD%20 INFORME%202021.pdf
Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985;254(22):3187-9.
Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, et al.. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol. 2014;20(30):10383-94.
Vitaliti G, Praticò AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, et al. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol. 2013;19(6):838-45.
Chang Y, Yao T, Shi J, Wu YT, Yang F, Yuan CL, et al. [Non/hypo-response to hepatitis B vaccination and influencing factors in HIV-infected patients in the context of different immunization schedules]. Zhonghua Liu Xing Bing Xue Za Zhi. 2022;43(5):696-701.
Nie L, Hua W, Liu X, Pang X, Guo C, Zhang W, et al. Associated Factors and Immune Response to the Hepatitis B Vaccine with a Standard Schedule: A Prospective Study of People with HIV in China. Vaccines (Basel). 2023;11(5):921.
Martins S, Livramento AD, Andrigueti M, Kretzer IF, Machado MJ, Spada C, et al. Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil. Braz J Infect Dis. 2015;19(2):181-6.
Paris RM, Milagres LG, Moysi E, Okulicz JF, Agan BK, Ganesan A, et al. Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection. Pathog Immun. 2017;2(1):66-88.
Seremba E, Ocama P, Ssekitoleko R, Mayanja- Kizza H, Adams SV, Orem J, et al. Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda. Vaccine. 2021;39(8):1265-1271.
Öztürk S, Özel AS, Ergen P, Şenbayrak S, Ağalar C. Hepatitis B immunization data of patients living with HIV/AIDS: a multi-centre study. Cent Eur J Public Health. 2022;30(4):213-218.
Feng YL, Chang Y, Shi J, Lan GH, Lu HY, Xiang SM, et al. [Immunization effect and persistence of hepatitis B vaccine in HIV-infected patients with different CD4+T cell levels]. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(9):1559-1565.
Aguilar-Urbina EW, García-Tello AV, Hilario-Vargas J, Concepción-Urteaga LA, Maguiña-Vargas C. Factores asociados a respuesta inadecuada a la vacuna de hepatitis B en pacientes con VIH. Rev Gastroenterol. 2019;39(3):252-257.
Mizusawa M, Perlman DC, Lucido D, Salomon N. Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2014;25(3):201-206.
Chatkittikunwong G, Khawcharoenporn T. Hepatitis B revaccination in HIV-infected vaccine non-responders: is double dosing always necessary?. Int J STD AIDS. 2016;27(10):850-855.
Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV- 1 (ANRS HB04 B-BOOST): a multicentre, open- label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283-1291.
Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, Espinosa N, Viciana P, López-Cortés LF. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine. 2019;37(20):2758-2763.
Rech-Medeiros AF, Marcon PDS, Tovo CDV, de Mattos AA. Evaluation of response to hepatitis B virus vaccine in adults with human immunodeficiency virus. Ann Hepatol. 2019;18(5):725-729.
Vargas JI, Jensen D, Martínez F, Sarmiento V,Peirano F, Acuña P, et al. Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(8):e2120929.
Feng Y, Yao T, Chang Y, Gao L, Shao Z, Dong S, et al. Immunogenicity and persistence of high- dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial. Vaccine. 2021;39(27):3582-3589.
Lara AN, Sartori AM, Fonseca MO, Lopes MH. Long-term protection after hepatitis B vaccination in people living with HIV. Vaccine. 2017;35(33):4155-4161.
Alon D, Stein GY, Hadas-Golan V, Tau L, Brosh T, Turner D. Immunogenicity of Sci-B-Vac (a Third- Generation Hepatitis B Vaccine) in HIV-Positive Adults. Isr Med Assoc J. 2017;19(3):143-146.
Khaimova R, Fischetti B, Cope R, Berkowitz L, Bakshi A. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. Vaccine. 2021;39(44):6529-6534.
Fernández-Prada M, Rodríguez-Fonseca OD, Brandy-García AM, Alonso-Penanes P, Huerta- González I, Fernández-Noval F. Uso de vacuna frente a hepatitis B adyuvada con AS04C en pacientes VIH. Rev Esp Quimioter. 2018;31(2):105- 109.
Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015;40(6):584-592.
Ghamar-Chehreh ME, Agah S, Khedmat H, Aghaei A, Alavian SM. Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis. Caspian J Intern Med. 2017;8(4):250-257.
Asan A, Demirhan H, Sorkun HÇ, Özkan S, Aydın M, Akın D, Tatar B, Çatak B, Şener A, Köse Ş. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol. 2017;49(10):1845-1850.
El-Charabaty E, Saifan C, Samarneh MM, El- Sayegh S. Variability in response to hepatitis B vaccine in hemodialysis patients. J Clin Med Res. 2015;7(5):315-318.
Friedrich P, Sattler A, Müller K, Nienen M, Reinke P, Babel N. Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients. Am J Transplant.2015;15(12):3157-3165.
Kengibe PY, Makulo JR, Nlandu YM, Lepira FB, Sumaili EK, Bukabau JB, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J. 2019;34:122.
Ramaswami AP, Pawar B, Pawar G, Brown M. Prevalence of blood-borne viruses and hepatitis B vaccination status among haemodialysis patients in Central Australia. IJID Reg. 2022;5:111- 116.
Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-VacTM, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018;22(1):151-158.
Kauke T, Link M, Rentsch M, Stangl M, Guba M, Andrassy J, et al. Antibody response to HBV vaccination on dialysis does not correlate with the development of deNovo anti-HLA antibodies after renal transplantation. Transpl Immunol. 2017;42:5-8.
Yousaf F, Gandham S, Galler M, Spinowitz B, Charytan C. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Ren Fail. 2015;37(7):1080-1088.
Fabrizi F, Cerutti R, Garcia-Agudo R, Bellincioni C, Porata G, Frontini G, et al. Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial. Clin Res Hepatol Gastroenterol. 2020;44(6):905-912.
Fabrizi F, Cerutti R, Nardelli L, Tripodi F, Messa P. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population. Clin Res Hepatol Gastroenterol. 2020;44(1):49-56.
Manley HJ, Aweh G, Frament J, Ladik V, Lacson EK. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. Nephrol Dial Transplant. 2023;38(2):447-454.
Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8.
Richi P, Alonso O, Martín MD, González-Hombrado L, Navío T, Salido M, et al. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol. 2020;39(9):2751- 2756.
Fernández-Prada M, Brandy-García AM, Rodríguez-Fonseca OD, Alonso-Penanes P, Latorre-Royán JV, Fernández-Peón I, et al. Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies. Vaccine. 2023;41(3):744-749.
Thomas RJ, Fletcher GJ, Kirupakaran H, Chacko MP, Thenmozhi S, Eapen CE, et al. Prevalence of non-responsiveness to an indigenous recombinant hepatitis B vaccine: a study among South Indian health care workers in a tertiary hospital. Indian J Med Microbiol. 2015;33(Suppl 1):32-6.
Krawczyk A, Ludwig C, Jochum C, Fiedler M, Heinemann FM, Shouval D, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014;32(39):5077-5082.
Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, Lu SN. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int. 2005;25(6):1162-1168.
Mendívil S, Arana CA, Aguirre W. Factors associated with the non-development of immunogenicity in vaccinated adults against the hepatitis B virus. Vacunas. 2021;22(3):158-66.
Körber N, Pohl L, Weinberger B, Grubeck B, Wawer A, Knolle PA, et al. Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24 high CD38 high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders. Front Immunol. 2021;10(12):713351.
Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L, et al. Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine. 2014;32(41):5316-22.
Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL. Universal Hepatitis B Vaccination In Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices-United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477- 83.
Ministerio de Salud y Protección Social, Empresa Nacional Promotora del Desarrollo Territorial eInstituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica basada en la evidencia científica para la atención de la infección por VIH/SIDA en personas adultas, gestantes y adolescentes. Versión para profesionales de salud. Bogotá D.C., Colombia. 2021. https://www.minsalud.gov. co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ ET/gpc-vih- adultos-version-profesionales-salud. pdf
Silva E, Roncancio GE, Forero J, Mesa JG, Cárdenas JG, Estévez M, et al. Colombian consensus on vaccination in patients with chronic kidney disease. Rev. Colomb. Nefrol. 2022;9(3):e649.
AEP: Asociación Española de Pediatría [Internet].. Madrid: Comité Asesor de Vacunas. Hepatitis B. Manual de inmunizaciones en línea de la AEP; 2023 Ene [citado 2023 septiembre 10]. Disponible en: http://vacunasaep.org/documentos/manual/ cap-29
CIMA[Internet]. Ficha técnica Fendrix, suspension inyectable; 2023 Abr 26 [citado 2023 septiembre 27]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/04299001/ FT_04299001.html
Colombia. Ministerio de Salud y Protección social. Lineamientos para garantizar la vacunación contra la hepatitis B a las víctimas de violencia sexual. Circular Minsalud DPS 0031 (Mayo 22, 2014).
Colombia. Ministerio de Salud y Protección Social. Instructivo para el uso del kit de profilaxis post exposición para VIH, ITS y anticoncepción de emergencia en víctimas de violencia sexual (Julio 26, 2012).
Ministerio de Salud y Protección Social. Dirección de Promoción y Prevención, Grupo de Sexualidad y Derechos Sexuales y Reproductivos. Protocolo para la atención por exposición de riesgo biológico laboral o no laboral, ante las infecciones de transmisión sexual, el virus de inmunodeficiencia humana, el virus de la Hepatitis B y el virus de la Hepatitis C. Bogotá D.C., Colombia. 2017. https://www.minsalud.gov.co/ sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/ protocol o-riesgo-biologico-its-vih-hepatits.pdf
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Médicas UIS